January 12, 2023 News by Andrea Lobo, PhD Quanterix Poised to Launch Test That Monitors NfL Levels Quanterix Corporation‘s laboratory test designed to measure blood levels of neurofilament light chain (NfL) has been validated by the Clinical Laboratory Improvement Amendments (CLIA), an arm of the U.S. Food and Drug Administration (FDA) that regulates laboratory testing. The company now is planning to launch its laboratory developed test,…
April 28, 2022 News by Lindsey Shapiro, PhD Blood Biomarker Test Granted Breakthrough Device Status by FDA Quanterixās ultra-sensitive blood test that measures a biomarker of nerve damage in people with multiple sclerosis (MS) has been granted a breakthrough device designation by U.S. regulators. It is thought that the test, which employs the companyās Simoa technology, can accurately predict the risk of disease activity in…
April 12, 2022 News by Marta Figueiredo, PhD New Blood Biomarker Technology May Help to Predict MS Activity Simoa, a technology that detects relevant molecules in samples with up to 1,000 times greater sensitivity than conventional methods, has helped to advance research into a blood biomarker expected to predict future disease activity in multiple sclerosis (MS) patients. Specifically, Quanterix‘s ultra-sensitive technology allowed an international team…
November 7, 2019 News by Ana Pena PhD Siemens Healthineers Joins with Quanterix to Develop Blood Tests for NfL Levels Siemens Healthineers has signed a license and supply agreement with Quanterix that helps it in developing blood tests for neurofilament light chain (NfL) to aid in early disease detection, evidence of progression, and measuring treatment response in people with neurological disorders such asĀ multiple sclerosis (MS). Siemens Healthineers…
May 8, 2019 News by Ana Pena PhD #AANAM ā Quanterix Leads Research on Neurofilament Light Chain as Potential MS Biomarker Quanterix is leading the research presented at this year’s American Academy of Neurology (AAN) Annual Meeting, validating the use of neurofilament light chain (NfL) as a potential biomarker for the diagnosis, prognosis, and treatment monitoring of patients with multiple sclerosis (MS) and other neurodegenerative diseases. The company…
August 8, 2018 News by Alice MelĆ£o, MSc Quanterixās Simoa Assay May Make Neurofilament Light Chain Useful Blood Biomarker of MS and Its Likely Progression Quanterixās ultra-sensitive Simoa assay has the potential to open new uses for the brain biomarker known as neurofilament light chain, including the possibility to detect early evidence of neurological diseases like multiple sclerosis (MS),Ā Parkinsonās, and Alzheimerās, and ably evaluate efforts to treat and prevent them,Ā the company…
November 17, 2016 News by Patricia Silva, PhD Assay Able to Detect Neuron Damage in Blood May Serve as Early MS Diagnostic Tool Quanterix and UmanDiagnosticsĀ are workingĀ to advanceĀ an assay capable of detecting neuron damage in a blood sample ā a tool that could aid in the earlyĀ diagnosis of multiple sclerosis (MS) and other neurodegenerative conditions. The collaboration brings Quanterixā Simoa technology together with Umanās antibodies against neurofilament light (Nf-L) ā a…